Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-10-26 | "Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs... Dr. Kropotova received her Master of Business Administration Degree... and her Medical Degree in Internal Medicine" |
| 2022-05-24 | Dr. Alexandra Kropotova(3) ... Includes 119,140 shares of Common Stock underlying options that will vest within 60 days of May 12, 2022 or will be fully vested within sixty days of May 12, 2022. |
| 2022-10-26 | "Dr. Kropotova is a biopharmaceutical executive ... Dr. Kropotova received her Master of Business Administration Degree ... and her Medical Degree in Internal Medicine" |
| 2023-10-26 | "Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs." |
| 2024-10-10 | "Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development... Dr. Kropotova received her Master of Business Administration Degree... and her Medical Degree..." |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-25